BMEA 11.65 Biomea Fusion, Inc.
| Range: | 3.61-22.74 | Vol Avg: | 795000 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | -0.45 | Cap: | 0.39B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Apr 16 2021 | Empoloyees: | 112 | ||
| CUSIP: | 09077A106 | CIK: | 0001840439 | ISIN: | US09077A1060 | Country: | US |
| CEO: | Mr. Thomas Andrew Butler | Website: | https://biomeafusion.com | ||||
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Stock Details
Positive 0.33
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or ...
globenewswire.com·Thu Sep 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow